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Background: The aim of this study was to investigate the minimally invasive cardiopulmonary bypass (CPB) and
deep hypothermic circulatory arrest (DHCA) approach in the management of renal cell carcinoma (RCC) with level
III or IV inferior vena cava (IVC) thrombus and evaluate the survival outcomes.
Methods: We performed a retrospective analysis on 32 RCC patients with IVC thrombus that underwent
nephrectomy and thrombectomy via the minimally invasive CPB/DHCA approach between January 2007 and
December 2013. Perioperative variables (for example, operative time, CPB duration, and circulatory arrest duration),
estimated blood loss, hospital stay, perioperative complications, and survival data were recorded and analyzed.
Results: Thirty-two patients (median age: 56 years) were treated surgically using the CPB and DHCA approach for
RCC with a level III (n = 25) or level IV (n = 7) tumor thrombus. The median operation time was 360 min
(interquartile range (IQR): 300 to 435 min) with median CPB and DHCA durations of 149 min and 23 min,
respectively. The median estimated blood loss was 2,500 ml. Four complications were observed but no deaths
occurred perioperatively. The median follow-up was 25 months (range: 4 to 64 months). The mean overall survival
(OS) was 28.2 ± 4.6 months while the disease-free survival (DFS) was 19.5 ± 11.6 months. In patients with M0 disease,
ten patients developed metastases and were treated with sorafenib as an adjuvant therapy. The mean OS and DFS
of this subgroup were 25.4 ± 12.8 months and 16.0 ± 14.2 months, respectively.
Conclusions: Radical nephrectomy and thrombectomy using CPB and DHCA to treat RCC is a relatively safe
approach associated with low morbidity and mortality. This minimally invasive procedure may help minimize
surgical trauma and improve perioperative outcomes.
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Renal cell carcinoma (RCC), one of the most common
forms of genitourinary malignancy, accounts for 3% of
all solid neoplasms [1]. Due to an increase in high-
resolution imaging, the incidence of RCC detection has
increased. In approximately 20% to 30% of RCC cases,* Correspondence: liudm541@126.com; yiranhuangrenji@163.com
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diagnosis or develop metastases after surgery [2]. More-
over, 4% to 10% of RCC patients also have a thrombus
involving the inferior vena cava (IVC), and the tumor
thrombus extends into the right atrium in 1% of these
patients [3,4].
The intravascular growth observed in RCC patients
could signify a heightened or more aggressive biologic
behavior of the tumor. However, some authors agree that
the RCC-associated tumor thrombus does not translate to
a specific prognostic significance if it can be treatedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 MRI of a right-sided renal cell carcinoma with right atrial
tumor thrombus.
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with IVC thrombus, several different surgical approaches
such as liver transplantation [6,7] and thrombectomy
using cardiopulmonary bypass (CPB) and deep hypother-
mic circulatory arrest (DHCA) [8,9] have been described.
New developments in imaging, anesthesiology, and peri-
operative care have allowed for most thrombi to be re-
moved successfully. There is, however, still considerable
morbidity and mortality associated with treatment of this
disease [10].
In the present study, we have retrospectively reviewed
our management of RCC cases with level III and IV
thrombi in a Chinese population using the minimally
invasive CPB with DHCA approach. To the best of our
knowledge, this study represents the largest analysis of




After Institutional Ethics Committee’s approval, we
retrospectively reviewed all level III and IV tumor
thrombus RCC cases operated on in the Urology Depart-
ment of Ren Ji Hospital at Shanghai Jiao Tong University
from January 2007 to December 2013. Tumor thrombus
staging was performed according to the guidelines estab-
lished by Neves and Zincke [11]. In total, 32 patients
were included in this study. All patients were preopera-
tively evaluated with ultrasound, computed tomography
(CT), or magnetic resonance imaging (MRI). To evaluate
metastases, additional imaging modalities such as chest
radiography, brain and lung CTs, and bone scans or
PET-CT were employed if necessary. Clinicopathological
features, including gender, age, which kidney was in-
volved, tumor size, histological type, and tumor grade
were obtained and analyzed. The total operation time,
duration of the DHCA, estimated blood loss, number of
transfusions and complications were also evaluated.
One patient in the case series, a 51-year-old man, pre-
sented with right kidney RCC and an IVC thrombus ex-
tending to the level of the diaphragm. Magnetic resonance
angiography accurately depicted the cranial extension of
the neoplastic thrombus (Figure 1). Results of lung CT
and bone scan were negative. The patient has given con-
sent for the report to be published.
Operative technique
After the patient was placed in a supine position, a para-
rectal incision alongside the abdominal rectus incision
(left: chevron incision) was made (Figure 2) and the ab-
domen was examined for evidence of tumor metastasis.
The IVC and kidney were exposed, and the IVC was
subsequently mobilized at the anterior surface only. An
incision in the right groin was then made to expose theright femoral artery, and a minithoracotomy was perfor-
med in the fourth intercostal space to open the pericar-
dium. Pericardial stay sutures were then passed through
and stabilized outside the chest. The patient was systemic-
ally heparinized. The femoral artery and the right atrium
were cannulated. The patient was placed on CPB and
cooled to 18°C. DHCA was performed according to the
protocol described by Welz et al. [12].
The IVC was mobilized as close to the diaphragm as
possible, and the cephalad extension and the mobility of
the tumor thrombus were confirmed using laparosono-
graphy. The venous collaterals, and the lumbar veins in
particular, were ligated and sectioned, as hemorrhaging
from these enlarged vessels is difficult to manage. After
ligation of the lumbar veins, an anterior cavatomy was
made to enable complete thrombus extraction. If neces-
sary, an atriotomy was performed to gently milk the
thrombus through the atriotomy into the IVC (Figure 3).
After the thrombus was extracted from the IVC, laparos-
copy or flexible cystoscopy was used to confirm complete
tumor removal and whether the tumor was adherent to
the IVC wall (Figure 4). If adherence was observed, a re-
section of the affected IVC segment was also performed.
Prior to closure, a small IVC cuff at the renal vein
junction was also taken. The right atrium and IVC were
closed with 5-0 Prolene running sutures. After caval
reconstruction and closure of the right atrium, the CPB
was reestablished and the patient was rewarmed to 36°C.
During this procedure, a radical nephrectomy was also
performed (Figure 5).
Results
Between January 2007 to December 2013, 32 consecutive
RCC cases (19 men, 13 women) with a level III (n = 25) or
level IV (n = 7) tumor thrombus underwent thrombectomy
Figure 3 Atriotomy revealing a large atrial tumor thrombus.
Figure 4 Laparoscopy was used to confirm the complete removal
of the thrombus and determine whether the tumor was adherent to
the IVC wall.
Figure 2 Incisions used for a right-sided tumor. An incision in the
fourth intercostal space (A) and the right groin (C) were made to
cannulate the superior vena cava and femoral artery. A subcostal
incision alongside the abdominal rectus incision was made to expose
the right renal and inferior vena cava (B).
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(Table 1). At the time of surgery, the median age was
56 years (IQR: 48 to 62 years). In 12 (37.5%) patients, the
tumor was located on the left while 20 (62.5%) patients
had a right-sided tumor.
The median total operation time was 360 min with
median CPB and DHCA durations of 149 min and
23 min, respectively. The median estimated blood loss
was 2,500 ml (IQR: 1,650 to 4,500), and 31 patients
required a blood transfusion, with a median estimated
blood transfusion volume of 2,600 ml (IQR: 1,000 to
4,400). The decision to administer blood was based on
the degree of blood loss and on preoperative hemoglobin
levels.Four complications were observed in this patient co-
hort: acute renal failure (n = 1), liver dysfunction (n = 1),
cardiac failure (n = 1), and coagulopathy (n = 1). We did
not observe any cases of tumor embolism and no mor-
talities occurred due to surgical complications. Patients
remained in the hospital for a median of 7 days (range: 5
to 10), and 1.5 days in the intensive care unit (range: 1
to 3). Pathologic examination of the tumors revealed
that 25 (78.1%) patients had clear cell RCC, five (15.6%)
patients had papillary RCC, and two (6.3%) patients had
primitive neuroectodermal tumors (PENT). Three pa-
tients presented with tumor thrombi that invaded the
IVC wall, such that part of the IVC luminal wall was
resected. The longitudinal caval incision was closed with
running sutures and none of the patients required IVC
segment resection or IVC grafts. The median tumor size
was 12 cm (range: 8 to 20).
Figure 5 The specimen and tumor thrombus of a renal cell carcinoma
patient with right atrial tumor thrombus invasion.
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(range: 4 to 64). The mean overall survival (OS) period
of the cohort was 28.2 ± 4.6 months, while the disease-
free survival (DFS) period was 19.5 ± 11.6 months. Two
patients (6.25%) in our population had M1 disease,
which is lower than what has been reported in other
previously published cohorts, and both of these pa-
tients died. The mean OS of the two M1 patients was
4.5 months. In the patients with M0 disease, ten (33.3%)
developed metastases. All patients with metastases wereTable 1 Baseline characteristics of the patients
Parameters Values
Number of patients, n 32
Median age (IQR), years 56 (48 to 62)
Male/female, n 19/13
Left/right kidney, n 12/20
Thrombus level III/IV, n 25/7
Median tumor size (range), centimeters 12 (8 to 20)
Median (IQR) duration of
Surgery, minutes 360 (300 to 435)
CPB, minutes 149 (138 to 177)
DHCA, minutes 23 (17 to 32)
Patients requiring IVC grafts, n 0
Median hospital stay (range), days 7 (5 to 10)









CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; IQR,
interquartile range; PENT, primitive neuroectodermal tumor.administered sorafenib as an adjuvant therapy. The mean
OS and DFS of this subgroup were 25.4 ± 12.8 months
and 16.0 ± 14.2 months, respectively. The mean OS of
patients without metastases was 33.0 ± 18.7 months.
Discussion
Medical therapies have proven ineffective in the treat-
ment of RCC with IVC thrombosis, and radical nephrec-
tomy together with thrombectomy is the only effective
therapeutic alternative for these patients [9,13]. Surgical
management of RCC in which there is extension into
the renal vein, IVC, or even the right atrium, however,
poses a significant technical challenge [10]. With the
technological advances in imaging, anesthesiology, and
cardiosurgery, surgical treatment of RCC with an IVC
thrombus is now feasible, and the thrombus can almost
always be removed successfully.
Although the benefit of CPB and DHCA in RCC
patients with level IV thrombus is obvious, controversy
still persists in the treatment of RCC patients with a level
III thrombus. Some experts suggest the use of non-
extracorporeal circulation and hypothermic circulatory ar-
rest to facilitate the removal of the tumor thrombus [6,7].
High level thrombi can also be managed with venovenous
bypass via a caval-atrial shunt [14]. This technique avoids
CPB and circulatory arrest, but it may result in hepatic
venous bleeding even when performed by experienced
surgeons. At our institution, we prefer an extracorporeal
circulation approach, as the use of CPB and DHCA de-
crease the risk for unexpected and life-threatening intra-
operative hemorrhage and incomplete tumor extirpation,
which are the primary goals of the surgery. With help
from the Department of Cardiac Surgery, CPB and DHCA
have been used to treat RCC with level III or IV IVC
thrombi in our hospital since 1997.
We have made some technical modifications to this
surgical approach in comparison to the published pro-
cedure [12]. First, after a pararectal (for right RCC) or
chevron incision (for left RCC) was made and the metas-
tases were assessed, only the anterior part of the IVC
was mobilized to reduce kidney mobilization to prevent
tumor embolism. Second, none of the patients in this
cohort underwent preoperative renal artery embolization,
as it is associated with increased complications and peri-
operative mortality [13]. Third, a minithoracotomy was
performed in the fourth intercostal space in lieu of a me-
dian sternotomy to open the pericardium. A minithora-
cotomy allows for a rapid postoperative recovery and
reduces the use of analgesics and the length of hospital
stay [15]. As previously reported [8], because the mini-
thoracotomy has only a small incision, there are esthetic
advantages. This technique is faster and has fewer require-
ments for mechanical ventilation and transfusion than
traditional median sternotomy [8,9].
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during the procedure of cooling the body to a core
temperature of 18°C, the IVC was mobilized. Once DHCA
was achieved, the thrombectomy was performed. After
vascular reconstruction was complete, the patient was
rewarmed. During the rewarming period, a radical neph-
rectomy and lymphadenectomy were performed. Perform-
ing the nephrectomy and lymphadenectomy during the
rewarming period reduces the waiting time during the
cardiosurgical portion of the procedure and shortens the
total operation time.
IVC thrombus is often associated with tumor metasta-
sis. Most of the previously published cohorts report that
30% of patients have M1 disease [3], and IVC thrombec-
tomy is advocated as it may relieve the symptoms and
potentially allow for a better quality of life [3,10]. Post-
operative targeted adjuvant therapy with either sorafenib
or sunitinib in patients with clear cell RCC, who are at a
high risk for disease recurrence, and it is effective in
reducing the recurrence rate [16]. This promising result
warrants further analysis in randomized clinical trials
with larger patient populations.
Our study has several limitations. It was performed
retrospectively in a single institution, and there was some
bias in patient selection. The study population was small
and the number of patients with M1 disease was lower
than other published series [3,8]. Future studies should be
conducted to compare this technique with other surgical
techniques for the management of RCC with a level III or
IV tumor thrombus.
Conclusions
Patients with level III or IV IVC thrombus RCC can be
treated safely and effectively via radical nephrectomy
and thrombectomy using CPB combined with DHCA.
This approach is associated with low rates of morbidity
and mortality. Introduction of a right anterior minithor-
acotomy may minimize surgical trauma, accelerate post-
operative recovery, and improve perioperative outcomes.
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